114 results on '"MacIntyre EA"'
Search Results
2. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease: Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia
- Author
-
van Dongen, JJM, Macintyre, EA, Gabert, JA, Delabesse, E, Rossi, V, Saglio, G, Gottardi, E, Rambaldi, A, Dotti, G, Griesinger, F, Parreira, A, Gameiro, P, Diáz, M González, Malec, M, Langerak, AW, San Miguel, JF, and Biondi, A
- Published
- 1999
- Full Text
- View/download PDF
3. Quantitative RNA slot-blot analysis of CCND1/cyclin D1 expression in suspected mantle cell lymphoma
- Author
-
Mauvieux, L, Canioni, D, Hermine, O, Valensi, F, Radford-Weiss, I, Azagury, M, Magen, M, Flandrin, G, Brousse, N, Varet, B, and Macintyre, EA
- Published
- 1998
- Full Text
- View/download PDF
4. A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell Clonality: A Comparative Study from the EuroClonality Consortium
- Author
-
Armand, M, Derrieux, C, Beldjord, K, Wabeke, Tamara, Lenze, D, Boone, E, Bruggemann, M, Evans, PAS, Gameiro, P, Hummel, M, Villarese, P, Groenen, P, Langerak, Ton, Macintyre, EA, Davi, F, Armand, M, Derrieux, C, Beldjord, K, Wabeke, Tamara, Lenze, D, Boone, E, Bruggemann, M, Evans, PAS, Gameiro, P, Hummel, M, Villarese, P, Groenen, P, Langerak, Ton, Macintyre, EA, and Davi, F
- Published
- 2019
5. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
- Author
-
Bruggemann, M, Kotrova, M, Knecht, H, Bartram, J, Boudjogrha, M, Bystry, V, Fazio, G, Fronkova, E, Giraud, M, Grioni, A, Hancock, J, Herrmann, D, Jimenez, C, Krejci, A, Moppett, J, Reigl, T, Salson, M, Scheijen, B, Schwarz, M, Songia, S, Svaton, M, van Dongen, JJM, Villarese, P, Wakeman, S, Wright, G, Cazzaniga, G, Davi, F, Garcia-Sanz, R, Gonzalez, D, Groenen, P, Hummel, M, Macintyre, EA, Stamatopoulos, K, Pott, C, Trka, J, Darzentas, N, Langerak, Ton, Bruggemann, M, Kotrova, M, Knecht, H, Bartram, J, Boudjogrha, M, Bystry, V, Fazio, G, Fronkova, E, Giraud, M, Grioni, A, Hancock, J, Herrmann, D, Jimenez, C, Krejci, A, Moppett, J, Reigl, T, Salson, M, Scheijen, B, Schwarz, M, Songia, S, Svaton, M, van Dongen, JJM, Villarese, P, Wakeman, S, Wright, G, Cazzaniga, G, Davi, F, Garcia-Sanz, R, Gonzalez, D, Groenen, P, Hummel, M, Macintyre, EA, Stamatopoulos, K, Pott, C, Trka, J, Darzentas, N, and Langerak, Ton
- Published
- 2019
6. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
- Author
-
Knecht, H, Reigl, T, Kotrova, M, Appelt, F, Stewart, P, Bystry, V, Krejci, A, Grioni, A, van der Pal, K, Stranska, K, Plevova, K, Rijntjes, J, Songia, S, Svaton, M, Fronkova, E, Bartram, J, Scheijen, B, Herrmann, D, Garcia-Sanz, R, Hancock, J, Moppett, J, van Dongen, JJM, Cazzaniga, G, Davi, F, Groenen, P, Hummel, M, Macintyre, EA, Stamatopoulos, K, Trka, J, Langerak, Ton, Gonzalez, D, Pott, C, Bruggemann, M, Darzentas, N, Knecht, H, Reigl, T, Kotrova, M, Appelt, F, Stewart, P, Bystry, V, Krejci, A, Grioni, A, van der Pal, K, Stranska, K, Plevova, K, Rijntjes, J, Songia, S, Svaton, M, Fronkova, E, Bartram, J, Scheijen, B, Herrmann, D, Garcia-Sanz, R, Hancock, J, Moppett, J, van Dongen, JJM, Cazzaniga, G, Davi, F, Groenen, P, Hummel, M, Macintyre, EA, Stamatopoulos, K, Trka, J, Langerak, Ton, Gonzalez, D, Pott, C, Bruggemann, M, and Darzentas, N
- Published
- 2019
7. High-throughput immunogenetics for clinical and research applications in immunohematology: Potential and challenges
- Author
-
Langerak, A, Brüggemann, M, Davi, F, Darzentas, N, Van Dongen, J, Gonzalez, D, Cazzaniga, G, Giudicelli, V, Lefranc, M, Giraud, M, Macintyre, E, Hummel, M, Pott, C, Groenen, P, Stamatopoulos, K, Langerak, AW, Van Dongen, JM, Lefranc, MP, Macintyre, EA, Groenen, PJTA, Langerak, A, Brüggemann, M, Davi, F, Darzentas, N, Van Dongen, J, Gonzalez, D, Cazzaniga, G, Giudicelli, V, Lefranc, M, Giraud, M, Macintyre, E, Hummel, M, Pott, C, Groenen, P, Stamatopoulos, K, Langerak, AW, Van Dongen, JM, Lefranc, MP, Macintyre, EA, and Groenen, PJTA
- Abstract
Analysis and interpretation of Ig and TCR gene rearrangements in the conventional, low-throughput way have their limitations in terms of resolution, coverage, and biases. With the advent of high-throughput, nextgeneration sequencing (NGS) technologies, a deeper analysis of Ig and/or TCR (IG/TR) gene rearrangements is now within reach, which impacts on all main applications of IG/TR immunogenetic analysis. To bridge the generation gap from low- to high-throughput analysis, the EuroClonality-NGS Consortium has been formed, with the main objectives to develop, standardize, and validate the entire workflow of IG/TR NGS assays for 1) clonality assessment, 2) minimal residual disease detection, and 3) repertoire analysis. This concerns the preanalytical (sample preparation, target choice), analytical (amplification, NGS), and postanalytical (immunoinformatics) phases. Here we critically discuss pitfalls and challenges of IG/TR NGS methodology and its applications in hemato-oncology and immunology.
- Published
- 2017
8. EuroClonality-NGS: aims and core projects
- Author
-
Langerak, Ton, Bruggemann, M, Cazzaniga, G, Darzentas, N, Davi, F, Dongen, Jacques, Gonzalez, D, Groenen, PJTA, Hummel, M, Macintyre, EA, Pott, C, Stamatopoulos, K, van Dongen, J.J.M., and Immunology
- Published
- 2015
9. Co Existence of LMPP Like and GMP Like Leukemia Stem Cells In Acute Myeloid Leukemia
- Author
-
Goardon, N, Marchi, E, Quek, L, Schuh, A, Woll, P, Mead, A, Alford, K, Gilkes, A, Beldjord, K, Bowen, D, Standen, G, Killick, S, Hunter, H, Knapper, S, Robinson, L, Sternberg, A, Cavenagh, JD, Virgo, P, Griffiths, M, Macintyre, EA, Craddock, C, Burnett, A, Enver, T, Jacobsen, SEW, Porcher, C, and Vyas, P
- Published
- 2010
10. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008
- Author
-
Brüggemann, M, Schrauder, A, Raff, T, Pfeifer, H, Dworzak, M, Ottmann, Og, Asnafi, V, Baruchel, A, Bassan, R, Benoit, Y, Biondi, A, Cavé, H, Dombret, H, Fielding, Ak, Foa, Roberto, Gökbuget, N, Goldstone, Ah, Goulden, N, Henze, G, Hoelzer, D, JANKA SCHAUB GE, Macintyre, Ea, Pieters, R, Rambaldi, A, Ribera, Jm, Schmiegelow, K, Spinelli, O, Stary, J, VON STACKELBERG, A, Kneba, M, Schrappe, M, VAN DONGEN JJ, EUROPEAN WORKING GROUP FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA EWALL, BFM SG, INTERNATIONAL BERLIN FRANKFURT MÜNSTER STUDY GROUP I., Pediatrics, Immunology, Brüggemann, M, Schrauder, A, Raff, T, Pfeifer, H, Dworzak, M, Ottmann, O, Asnafi, V, Baruchel, A, Bassan, R, Benoit, Y, Biondi, A, Cavé, H, Dombret, H, Fielding, A, Foà, R, Gökbuget, N, Goldstone, A, Goulden, N, Henze, G, Hoelzer, D, Janka Schaub, G, Macintyre, E, Pieters, R, Rambaldi, A, Ribera, J, Schmiegelow, K, Spinelli, O, Stary, J, von Stackelberg, A, Kneba, M, Schrappe, M, and van Dongen, J
- Subjects
Cancer Research ,medicine.medical_specialty ,Pediatrics ,Neoplasm, Residual ,Fusion Proteins, bcr-abl ,Context (language use) ,Acute lymphoblastic leukemia ,Polymerase Chain Reaction ,hemic and lymphatic diseases ,Medicine ,Humans ,Medical physics ,Flow cytometry ,Gene Rearrangement ,MRD Response ,Adult all ,Genes, Immunoglobulin ,business.industry ,Minimal residual disease ,Hematology ,Gene rearrangement ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,body regions ,Clinical trial ,MRD ,PCR ,Oncology ,Complete MRD Response ,MRD Reappearance ,business ,ALL - Abstract
Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.
- Published
- 2010
11. Clonity analysis for antigen receptor genes: preliminary results from the Biomed-2 concerted action PL 96-3936
- Author
-
van Krieken, JHJM, Langerak, Ton, San miguel, JF, Parreira, A, Smith, JL, Morgan, GM, Kneba, M, Macintyre, EA, Dongen, Jacques, and Immunology
- Published
- 2003
12. Clonality analysis in malignant lymphoma: the BIOMED-2 experience
- Author
-
Langerak, Ton, San miguel, JF, Parreira, A, Smith, JL, Morgan, G, Kneba, M, Macintyre, EA, van Krieken, JHJM, Dongen, Jacques, and Immunology
- Published
- 2002
13. Polymerase chain reaction-based clonality studies for early diagnosis of lymphoproliferative disorders
- Author
-
Dongen, Jacques, Langerak, Ton, San miguel, JF, Parreira, A, Smith, JL, Morgan, G, Kneba, M, Macintyre, EA, van Krieken, JHJM, and Immunology
- Published
- 2002
14. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations
- Author
-
Langerak, Ton, Groenen, PJTA, Bruggemann, M, Beldjord, K, Bellan, C, Bonello, L, Boone, E, Carter, GI, Catherwood, M, Davi, F, Delfau-Larue, MH, Diss, T, Evans, PAS, Gameiro, P, Sanz, RG, Gonzalez, D, Grand, D, Hakansson, A, Hummel, M, Liu, H, Lombardia, L, Macintyre, EA, Milner, BJ, Montes-Moreno, S, Schuuring, E, Spaargaren, M, Hodges, E, Dongen, Jacques, Langerak, Ton, Groenen, PJTA, Bruggemann, M, Beldjord, K, Bellan, C, Bonello, L, Boone, E, Carter, GI, Catherwood, M, Davi, F, Delfau-Larue, MH, Diss, T, Evans, PAS, Gameiro, P, Sanz, RG, Gonzalez, D, Grand, D, Hakansson, A, Hummel, M, Liu, H, Lombardia, L, Macintyre, EA, Milner, BJ, Montes-Moreno, S, Schuuring, E, Spaargaren, M, Hodges, E, and Dongen, Jacques
- Abstract
PCR-based immunoglobulin (Ig)/T-cell receptor (TCR) clonality testing in suspected lymphoproliferations has largely been standardized and has consequently become technically feasible in a routine diagnostic setting. Standardization of the pre-analytical and post-analytical phases is now essential to prevent misinterpretation and incorrect conclusions derived from clonality data. As clonality testing is not a quantitative assay, but rather concerns recognition of molecular patterns, guidelines for reliable interpretation and reporting are mandatory. Here, the EuroClonality (BIOMED-2) consortium summarizes important pre- and post-analytical aspects of clonality testing, provides guidelines for interpretation of clonality testing results, and presents a uniform way to report the results of the Ig/TCR assays. Starting from an immunobiological concept, two levels to report Ig/TCR profiles are discerned: the technical description of individual (multiplex) PCR reactions and the overall molecular conclusion for B and T cells. Collectively, the EuroClonality (BIOMED-2) guidelines and consensus reporting system should help to improve the general performance level of clonality assessment and interpretation, which will directly impact on routine clinical management (standardized best-practice) in patients with suspected lymphoproliferations.
- Published
- 2012
15. Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH- positive follicular lymphoma patients
- Author
-
Macintyre, EA, primary, Belanger, C, additional, Debert, C, additional, Canioni, D, additional, Turhan, AG, additional, Azagury, M, additional, Hermine, O, additional, Varet, B, additional, Flandrin, G, additional, and Schmitt, C, additional
- Published
- 1995
- Full Text
- View/download PDF
16. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia
- Author
-
Romana, SP, primary, Poirel, H, additional, Leconiat, M, additional, Flexor, MA, additional, Mauchauffe, M, additional, Jonveaux, P, additional, Macintyre, EA, additional, Berger, R, additional, and Bernard, OA, additional
- Published
- 1995
- Full Text
- View/download PDF
17. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia
- Author
-
Turhan, AG, primary, Lemoine, FM, additional, Debert, C, additional, Bonnet, ML, additional, Baillou, C, additional, Picard, F, additional, Macintyre, EA, additional, and Varet, B, additional
- Published
- 1995
- Full Text
- View/download PDF
18. Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage
- Author
-
Macintyre, EA, primary, Smit, L, additional, Ritz, J, additional, Kirsch, IR, additional, and Strominger, JL, additional
- Published
- 1992
- Full Text
- View/download PDF
19. Helix-loop-helix (E2-5, HEB, TAL1 and Id1) protein interaction with the TCRαδ enhancers.
- Author
-
Bernard, M, Delabesse, E, Smit, L, Millien, C, Kirsch, IR, Strominger, JL, and Macintyre, EA
- Abstract
In order to dissect the correlation between aberrant TAL1 basic-helix-loop-helix (b-HLH) expression and the exclusive development of T cell acute lymphoblastic leukemias (T-ALL) of the TCRαβ lineage, we have assessed the ability of class A b-HLH proteins to regulate the TCRα and δ enhancers. We demonstrate that E47S binds to TCRα but not to TCRδ E-boxes in vitro. Despite this, neither E2-5 nor HEB transactivate the TCRα enhancer in NIH 3T3, nor did Id1 modify endogenously driven TCRα [αE1-4] activity in a TCRαβ cell line. We also demonstrate that TAL-1 inhibits both binding of E47S to αE3 and αE4 and endogenous transactivation of the TCRα enhancer. Comparison of the activity of the minimal [αE1-2] fragment, which contains no E-boxes, with the accessory [αE3-4] fragment, which contains two, suggested some contribution from the latter to TCRα enhancer activity in HPB-ALL. TCR [αE1-2] activity was partially (40%) inhibited by TAL1 but not all by Id1. In contrast, [αE3-4] activity was almost completely inhibited by TAL1 (80%) and slightly reduced by Id1 (15%). These data demonstrate that class A b-HLH regulation of the TCRα enhancer E-boxes differs from their B lymphoid Igμ counterparts and suggest a novel mechanism on transcriptional inhibition by TAL1, which may be, at least partly, independent of E-box-mediated activation, as we currently recognize it. They also clearly demonstrate that the restriction of TAL1 deregulation to T-ALL of the TCRαβ lineage is not due to induction of TCRα enhancer activity by the TAL1 protein. [ABSTRACT FROM PUBLISHER]
- Published
- 1998
- Full Text
- View/download PDF
20. ATP citrate lyase is an essential player in the metabolic rewiring induced by PTEN loss during T-ALL development.
- Author
-
Andrieu GP, Hypolite G, Latiri M, Balducci E, Costa C, Verhoeyen E, Courgeon M, Allatif O, Nemazanyy I, Panasyuk G, Wellen KE, Herranz D, Genestier L, Macintyre EA, Asnafi V, and Tesio M
- Abstract
Alterations inactivating the tumor suppressor gene PTEN drive the development of solid and hematological cancers, such as T-cell acute lymphoblastic leukemia (T-ALL), whereby PTEN loss defines poor-prognosis patients. We investigated the metabolic rewiring induced by PTEN loss in T-ALL, aiming at identifying novel metabolic vulnerabilities. We showed that the enzyme ATP citrate lyase (ACLY) is strictly required for the transformation of thymic immature progenitors and for the growth of human T-ALL, which remain dependent on ACLY activity even upon transformation. Whereas PTEN mutant mice all died within 17 weeks, the concomitant ACLY deletion prevented disease initiation in 70% of the animals. In these animals, ACLY promoted BCL-2 epigenetic upregulation and prevented the apoptosis of pre-malignant DP thymocytes. Transcriptomic and metabolic analysis of primary T-ALL cells next translated our findings to the human pathology, showing that PTEN-altered T-ALL cells activate ACLY and are sensitive to its genetic targeting. ACLY activation thus represents a metabolic vulnerability with therapeutic potential for high-risk T-ALL patients., (Copyright © 2024 American Society of Hematology.)
- Published
- 2024
- Full Text
- View/download PDF
21. Multimodal cartography of human lymphopoiesis reveals B and T/NK/ILC lineages are subjected to differential regulation.
- Author
-
Alhaj Hussen K, Chabaane E, Nelson E, Lekiashvili S, Diop S, Keita S, Evrard B, Lardenois A, Delord M, Verhoeyen E, Cornils K, Kasraian Z, Macintyre EA, Cumano A, Garrick D, Goodhardt M, Andrieu GP, Asnafi V, Chalmel F, and Canque B
- Abstract
The developmental cartography of human lymphopoiesis remains incompletely understood. Here, we establish a multimodal map demonstrating that lymphoid specification follows independent direct or stepwise hierarchic routes converging toward the emergence of newly characterized CD117
lo multi-lymphoid progenitors (MLPs) that undergo a proliferation arrest before entering the CD127- (NK/ILC/T) or CD127+ (B) lymphoid pathways. While the differentiation of CD127- early lymphoid progenitors is mainly driven by Flt3 signaling, emergence of their CD127+ counterparts is regulated cell-intrinsically and depends exclusively on the divisional history of their upstream precursors, including hematopoietic stem cells. Further, transcriptional mapping of differentiation trajectories reveals that whereas myeloid granulomonocytic lineages follow continuous differentiation pathways, lymphoid trajectories are intrinsically discontinuous and characterized by sequential waves of cell proliferation allowing pre-commitment amplification of lymphoid progenitor pools. Besides identifying new lymphoid specification pathways and regulatory checkpoints, our results demonstrate that NK/ILC/T and B lineages are under fundamentally distinct modes of regulation. (149 words)., Competing Interests: The authors have no conflict of interest., (© 2023 The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
22. Lessons learned from implementing a surge capacity support program for COVID-19 contact management in Ontario.
- Author
-
Chambers A, Quirk J, MacIntyre EA, Bodkin A, and Hanson H
- Subjects
- Humans, Ontario epidemiology, Pandemics prevention & control, Surge Capacity, Public Health, Contact Tracing, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
Setting: In Ontario, local public health units (PHUs) are responsible for leading case investigations, contact tracing, and follow-up. The workforce capacity and operational requirements needed to maintain this public health strategy during the COVID-19 pandemic were unprecedented., Intervention: Public Health Ontario's Contact Tracing Initiative (CTI) was established to provide a centralized workforce. This program was unique in leveraging existing human resources from federal and provincial government agencies and its targeted focus on initial and follow-up phone calls to high-risk close contacts of COVID-19 cases. By setting criteria for submissions to the program, standardizing scripts, and simplifying the data management process, the CTI was able to support a high volume of calls., Outcomes: During its 23 months of operation, the CTI was used by 33 of the 34 PHUs and supported over a million calls to high-risk close contacts. This initiative was able to meet its objectives while adapting to the changing dynamics of the pandemic and the implementation of a new COVID-19 provincial information system. Core strengths of the CTI were timeliness, volume, and efficient use of resources. The CTI was found to be useful for school exposures, providing support when public health measures were lifted, and in supporting PHU's reallocation of resources during the vaccine roll-out., Implications: When considering future use of this model, it is important to take note of the program strengths and limitations to ensure alignment with future needs for surge capacity support. Lessons learned from this initiative could provide practice-relevant knowledge for surge capacity planning., (© 2023. Crown.)
- Published
- 2023
- Full Text
- View/download PDF
23. Clonotype definitions for immunogenetic studies: proposals from the EuroClonality NGS Working Group.
- Author
-
Sofou E, Vlachonikola E, Zaragoza-Infante L, Brüggemann M, Darzentas N, Groenen PJTA, Hummel M, Macintyre EA, Psomopoulos F, Davi F, Langerak AW, and Stamatopoulos K
- Subjects
- Humans, Receptors, Antigen, T-Cell genetics, High-Throughput Nucleotide Sequencing, Immunogenetics, Genes, Immunoglobulin
- Published
- 2023
- Full Text
- View/download PDF
24. Distinct subsets of multi-lymphoid progenitors support ontogeny-related changes in human lymphopoiesis.
- Author
-
Keita S, Diop S, Lekiashvili S, Chabaane E, Nelson E, Strullu M, Arfeuille C, Guimiot F, Domet T, Duchez S, Evrard B, Darde T, Larghero J, Verhoeyen E, Cumano A, Macintyre EA, Kasraian Z, Jouen F, Goodhardt M, Garrick D, Chalmel F, Alhaj Hussen K, and Canque B
- Subjects
- Adult, Humans, Aged, Cell Differentiation, Cell Lineage, Hematopoiesis, Lymphopoiesis, Hematopoietic Stem Cells
- Abstract
Changes in lymphocyte production patterns occurring across human ontogeny remain poorly defined. In this study, we demonstrate that human lymphopoiesis is supported by three waves of embryonic, fetal, and postnatal multi-lymphoid progenitors (MLPs) differing in CD7 and CD10 expression and their output of CD127
-/+ early lymphoid progenitors (ELPs). In addition, our results reveal that, like the fetal-to-adult switch in erythropoiesis, transition to postnatal life coincides with a shift from multilineage to B lineage-biased lymphopoiesis and an increase in production of CD127+ ELPs, which persists until puberty. A further developmental transition is observed in elderly individuals whereby B cell differentiation bypasses the CD127+ compartment and branches directly from CD10+ MLPs. Functional analyses indicate that these changes are determined at the level of hematopoietic stem cells. These findings provide insights for understanding identity and function of human MLPs and the establishment and maintenance of adaptative immunity., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
25. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders.
- Author
-
Stewart JP, Gazdova J, Darzentas N, Wren D, Proszek P, Fazio G, Songia S, Alcoceba M, Sarasquete ME, Villarese P, van der Klift MY, Heezen KC, McCafferty N, Pal K, Catherwood M, Kim CS, Srivastava S, Kroeze LI, Hodges E, Stamatopoulos K, Klapper W, Genuardi E, Ferrero S, van den Brand M, Cazzaniga G, Davi F, Sutton LA, Garcia-Sanz R, Groenen PJTA, Macintyre EA, Brüggemann M, Pott C, Langerak AW, and Gonzalez D
- Subjects
- DNA, Genomics, Humans, Immunoglobulins, Gene Rearrangement, Lymphoproliferative Disorders diagnosis, Lymphoproliferative Disorders genetics
- Abstract
Current diagnostic standards for lymphoproliferative disorders include multiple tests for detection of clonal immunoglobulin (IG) and/or T-cell receptor (TCR) rearrangements, translocations, copy-number alterations (CNAs), and somatic mutations. The EuroClonality-NGS DNA Capture (EuroClonality-NDC) assay was designed as an integrated tool to characterize these alterations by capturing IGH switch regions along with variable, diversity, and joining genes of all IG and TCR loci in addition to clinically relevant genes for CNA and mutation analysis. Diagnostic performance against standard-of-care clinical testing was assessed in a cohort of 280 B- and T-cell malignancies from 10 European laboratories, including 88 formalin-fixed paraffin-embedded samples and 21 reactive lesions. DNA samples were subjected to the EuroClonality-NDC protocol in 7 EuroClonality-NGS laboratories and analyzed using a bespoke bioinformatic pipeline. The EuroClonality-NDC assay detected B-cell clonality in 191 (97%) of 197 B-cell malignancies and T-cell clonality in 71 (97%) of 73 T-cell malignancies. Limit of detection (LOD) for IG/TCR rearrangements was established at 5% using cell line blends. Chromosomal translocations were detected in 145 (95%) of 152 cases known to be positive. CNAs were validated for immunogenetic and oncogenetic regions, highlighting their novel role in confirming clonality in somatically hypermutated cases. Single-nucleotide variant LOD was determined as 4% allele frequency, and an orthogonal validation using 32 samples resulted in 98% concordance. The EuroClonality-NDC assay is a robust tool providing a single end-to-end workflow for simultaneous detection of B- and T-cell clonality, translocations, CNAs, and sequence variants., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
26. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
- Author
-
Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, MacIntyre EA, Harrivel V, Desbrosses Y, Gruson B, Geneviève F, Thepot S, Drebit Y, Leguay T, Gros FX, Lechevalier N, Saussoy P, Salaun V, Cornet E, Benseddik Z, Veyrat-Masson R, Wagner-Ballon O, Salanoubat C, Maynadié M, Guy J, Caillot D, Jacob MC, Cahn JY, Gressin R, Rose J, Quesnel B, Guerin E, Trimoreau F, Feuillard J, Gourin MP, Plesa A, Baseggio L, Arnoux I, Vey N, Blaise D, Lacroix R, Arnoulet C, Benet B, Dorvaux V, Bret C, Drenou B, Debliquis A, Latger-Cannard V, Bonmati C, Bene MC, Peterlin P, Ticchioni M, Rohrlich PS, Arnaud A, Wickenhauser S, Bardet V, Brechignac S, Papoular B, Raggueneau V, Vargaftig J, Letestu R, Lusina D, Braun T, Foissaud V, Tamburini J, Bennani H, Freynet N, Cordonnier C, Le Garff-Tavernier M, Jacques N, Maloum K, Roos-Weil D, Bouscary D, Asnafi V, Lhermitte L, Suarez F, Lengline E, Féger F, Battipaglia G, Mohty M, Bouyer S, Ghoual O, Dindinaud E, Basle C, Puyade M, Lafon C, Fest T, Roussel M, Cahu X, Bera E, Daliphard S, Jardin F, Campos L, Solly F, Guyotat D, Galoisy AC, Eischen A, Mayeur-Rousse C, Guffroy B, Recher C, Loosveld M, Garnier A, Barlogis V, Rosenthal MA, Brun S, Contentin N, Maury S, Callanan M, Lefebvre C, Maillard N, Okamba P, Ferrand C, Adotevi O, Saas P, Angelot-Delettre F, Binda D, and Deconinck E
- Subjects
- Acute Disease, Biomarkers, Blood Cell Count, Bone Marrow pathology, Chromosome Aberrations, Clonal Evolution genetics, Dendritic Cells metabolism, Disease Management, Hematopoietic Stem Cell Transplantation, Humans, Immunophenotyping, Leukemia etiology, Leukemia metabolism, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Treatment Outcome, Dendritic Cells pathology, Leukemia diagnosis, Leukemia therapy
- Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed a nationwide network to collect data from new cases diagnosed in France. In a retrospective, observational study of 86 patients (2000-2013), we described clinical and biological data focusing on morphologies and immunophenotype. We found expression of markers associated with plasmacytoid dendritic cell origin (HLA-DRhigh, CD303+, CD304+, and cTCL1+) plus CD4 and CD56 and frequent expression of isolated markers from the myeloid, B-, and T-lymphoid lineages, whereas specific markers (myeloperoxidase, CD14, cCD3, CD19, and cCD22) were not expressed. Fifty-one percent of cytogenetic abnormalities impact chromosomes 13, 12, 9, and 15. Myelemia was associated with an adverse prognosis. We categorized chemotherapeutic regimens into 5 groups: acute myeloid leukemia (AML)-like, acute lymphoid leukemia (ALL)-like, lymphoma (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP])-like, high-dose methotrexate with asparaginase (Aspa-MTX) chemotherapies, and not otherwise specified (NOS) treatments. Thirty patients received allogeneic hematopoietic cell transplantation (allo-HCT), and 4 patients received autologous hematopoietic cell transplantation. There was no difference in survival between patients receiving AML-like, ALL-like, or Aspa-MTX regimens; survival was longer in patients who received AML-like, ALL-like, or Aspa-MTX regimens than in those who received CHOP-like regimens or NOS. Eleven patients are in persistent complete remission after allo-HCT with a median survival of 49 months vs 8 for other patients. Our series confirms a high response rate with a lower toxicity profile with the Aspa-MTX regimen, offering the best chance of access to hematopoietic cell transplantation and a possible cure., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
27. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
- Author
-
Brüggemann M, Kotrová M, Knecht H, Bartram J, Boudjogrha M, Bystry V, Fazio G, Froňková E, Giraud M, Grioni A, Hancock J, Herrmann D, Jiménez C, Krejci A, Moppett J, Reigl T, Salson M, Scheijen B, Schwarz M, Songia S, Svaton M, van Dongen JJM, Villarese P, Wakeman S, Wright G, Cazzaniga G, Davi F, García-Sanz R, Gonzalez D, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Pott C, Trka J, Darzentas N, and Langerak AW
- Subjects
- Computational Biology methods, Genes, Immunoglobulin genetics, High-Throughput Nucleotide Sequencing methods, Humans, Receptors, Antigen, T-Cell genetics, Recombination, Genetic genetics, Reference Standards, Reproducibility of Results, Gene Rearrangement, T-Lymphocyte genetics, Genes, T-Cell Receptor genetics, Genetic Markers genetics, Immunoglobulins genetics, Neoplasm, Residual genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification and quantification of minimal residual disease (MRD) in lymphoid neoplasms has been the focus of intense research, development and application. However, standardization and validation in a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay development and design, including bioinformatics, was performed within the EuroClonality-NGS working group and validated for MRD marker identification in acute lymphoblastic leukaemia (ALL). Five EuroMRD ALL reference laboratories performed IG/TR NGS in 50 diagnostic ALL samples, and compared results with those generated through routine IG/TR Sanger sequencing. A central polytarget quality control (cPT-QC) was used to monitor primer performance, and a central in-tube quality control (cIT-QC) was spiked into each sample as a library-specific quality control and calibrator. NGS identified 259 (average 5.2/sample, range 0-14) clonal sequences vs. Sanger-sequencing 248 (average 5.0/sample, range 0-14). NGS primers covered possible IG/TR rearrangement types more completely compared with local multiplex PCR sets and enabled sequencing of bi-allelic rearrangements and weak PCR products. The cPT-QC showed high reproducibility across all laboratories. These validated and reproducible quality-controlled EuroClonality-NGS assays can be used for standardized NGS-based identification of IG/TR markers in lymphoid malignancies.
- Published
- 2019
- Full Text
- View/download PDF
28. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS.
- Author
-
Knecht H, Reigl T, Kotrová M, Appelt F, Stewart P, Bystry V, Krejci A, Grioni A, Pal K, Stranska K, Plevova K, Rijntjes J, Songia S, Svatoň M, Froňková E, Bartram J, Scheijen B, Herrmann D, García-Sanz R, Hancock J, Moppett J, van Dongen JJM, Cazzaniga G, Davi F, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Trka J, Langerak AW, Gonzalez D, Pott C, Brüggemann M, and Darzentas N
- Subjects
- Computational Biology methods, Gene Rearrangement genetics, High-Throughput Nucleotide Sequencing methods, Humans, Neoplasm, Residual genetics, Quality Control, Reproducibility of Results, Genetic Markers genetics, Immunoglobulins genetics, Receptors, Antigen, T-Cell genetics
- Abstract
Assessment of clonality, marker identification and measurement of minimal residual disease (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under intensive development for use in clinical diagnostics. So far, however, there is a lack of suitable quality control (QC) options with regard to standardisation and quality metrics to ensure robust clinical application of such approaches. The EuroClonality-NGS Working Group has therefore established two types of QCs to accompany the NGS-based IG/TR assays. First, a central polytarget QC (cPT-QC) is used to monitor the primer performance of each of the EuroClonality multiplex NGS assays; second, a standardised human cell line-based DNA control is spiked into each patient DNA sample to work as a central in-tube QC and calibrator for MRD quantification (cIT-QC). Having integrated those two reference standards in the ARResT/Interrogate bioinformatic platform, EuroClonality-NGS provides a complete protocol for standardised IG/TR gene rearrangement analysis by NGS with high reproducibility, accuracy and precision for valid marker identification and quantification in diagnostics of lymphoid malignancies.
- Published
- 2019
- Full Text
- View/download PDF
29. A New and Simple TRG Multiplex PCR Assay for Assessment of T-cell Clonality: A Comparative Study from the EuroClonality Consortium.
- Author
-
Armand M, Derrieux C, Beldjord K, Wabeke T, Lenze D, Boone E, Bruggemann M, Evans PAS, Gameiro P, Hummel M, Villarese P, Groenen PJTA, Langerak AW, Macintyre EA, and Davi F
- Abstract
T-cell Receptor Gamma (TRG) rearrangements are commonly used to detect clonal lymphoproliferations in hematopathology, since they are rearranged in virtually all T lymphocytes and have a relatively limited recombinatorial repertoire, which reduces the risk of false negative results, at the cost of potential false positivity. We developed an initial one-tube, 2-fluorochrome EuroClonality TRG PCR multiplex (TRG-1T-2F) which was compared to the original 2-tube, 2-fluorochrome EuroClonality/BIOMED-2 TRG PCR (TRG-2T-2F) and a commercial Invivoscribe one-tube, one-fluorochrome kit (IVS-1T-1F) on a series of 239 samples, including both T-cell malignancies and reactive cases. This initial assay yielded discrepant results between the 10 participating EuroClonality laboratories when using 2 fluorochromes, leading to adoption of a final single color EuroClonality strategy (TRG-1T-1F). Compared to TRG-2T-2F, both TRG-1T-1F and IVS-1T-1F demonstrated easier interpretation and a lower risk of false positive from minor peaks in dispersed repertoires. Both generate smaller fragments and as such are likely to be better adapted to analysis of formalin-fixed paraffin-embedded (FFPE) tissue samples. Their differential performance was mainly explained by (i) superposition of biallelic rearrangements with IVS-1T-1F, due to more extensive overlapping of the repertoires and (ii) intentional omission of the TRGJP primer in TRG-1T-1F, in order to avoid the potential risk of confusion of consensus TRG V9-JP normal rearrangements with a pathological clone., Competing Interests: The authors have indicated they have no potential conflicts of interest to disclose., (Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)
- Published
- 2019
- Full Text
- View/download PDF
30. Successful in utero stem cell transplantation in X-linked severe combined immunodeficiency.
- Author
-
Magnani A, Jouannic JM, Rosain J, Gabrion A, Touzot F, Roudaut C, Kracker S, Mahlaoui N, Toubert A, Clave E, Macintyre EA, Radford-Weiss I, Alcantara M, Magrin E, Ternaux B, Nisoy J, Caccavelli L, Darras AM, Picard C, Blanche S, and Cavazzana M
- Subjects
- Child, Preschool, Female, Humans, X-Linked Combined Immunodeficiency Diseases pathology, Hematopoietic Stem Cell Transplantation methods, Transplantation Conditioning methods, X-Linked Combined Immunodeficiency Diseases therapy
- Published
- 2019
- Full Text
- View/download PDF
31. Atopic dermatitis: Interaction between genetic variants of GSTP1, TNF, TLR2, and TLR4 and air pollution in early life.
- Author
-
Hüls A, Klümper C, MacIntyre EA, Brauer M, Melén E, Bauer M, Berdel D, Bergström A, Brunekreef B, Chan-Yeung M, Fuertes E, Gehring U, Gref A, Heinrich J, Standl M, Lehmann I, Kerkhof M, Koppelman GH, Kozyrskyj AL, Pershagen G, Carlsten C, Krämer U, and Schikowski T
- Subjects
- Air Pollutants adverse effects, Air Pollutants analysis, Child, Child, Preschool, Dermatitis, Atopic epidemiology, Dermatitis, Atopic etiology, Female, Gene-Environment Interaction, Genetic Predisposition to Disease, Genetic Variation genetics, Genotype, Humans, Male, Polymorphism, Single Nucleotide, Risk Factors, Dermatitis, Atopic genetics, Glutathione S-Transferase pi genetics, Toll-Like Receptor 2 genetics, Toll-Like Receptor 4 genetics, Traffic-Related Pollution adverse effects, Tumor Necrosis Factor-alpha genetics
- Abstract
Background: Associations between traffic-related air pollution (TRAP) and childhood atopic dermatitis (AD) remain inconsistent, possibly due to unexplored gene-environment interactions. The aim of this study was to examine whether a potential effect of TRAP on AD prevalence in children is modified by selected single nucleotide polymorphisms (SNPs) related to oxidative stress and inflammation., Methods: Doctor-diagnosed AD up to age 2 years and at 7-8 years, as well as AD symptoms up to age 2 years, was assessed using parental-reported questionnaires in six birth cohorts (N = 5685). Associations of nitrogen dioxide (NO
2 ) estimated at the home address of each child at birth and nine SNPs within the GSTP1, TNF, TLR2, or TLR4 genes with AD were examined. Weighted genetic risk scores (GRS) were calculated from the above SNPs and used to estimate combined marginal genetic effects of oxidative stress and inflammation on AD and its interaction with TRAP., Results: GRS was associated with childhood AD and modified the association between NO2 and doctor-diagnosed AD up to the age of 2 years (P(interaction) = .029). This interaction was mainly driven by a higher susceptibility to air pollution in TNF rs1800629 minor allele (A) carriers. TRAP was not associated with the prevalence of AD in the general population., Conclusions: The marginal genetic association of a weighted GRS from GSTP1, TNF, TLR2, and TLR4SNPs and its interaction with air pollution supports the role of oxidative stress and inflammation in AD., (© 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)- Published
- 2018
- Full Text
- View/download PDF
32. High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges.
- Author
-
Langerak AW, Brüggemann M, Davi F, Darzentas N, van Dongen JJM, Gonzalez D, Cazzaniga G, Giudicelli V, Lefranc MP, Giraud M, Macintyre EA, Hummel M, Pott C, Groenen PJTA, and Stamatopoulos K
- Subjects
- Alleles, Computational Biology methods, Gene Rearrangement, Genes, Immunoglobulin, Genes, T-Cell Receptor genetics, Humans, Immunogenetics standards, Hematology methods, High-Throughput Nucleotide Sequencing methods, Immunogenetics methods, Immunologic Techniques
- Abstract
Analysis and interpretation of Ig and TCR gene rearrangements in the conventional, low-throughput way have their limitations in terms of resolution, coverage, and biases. With the advent of high-throughput, next-generation sequencing (NGS) technologies, a deeper analysis of Ig and/or TCR (IG/TR) gene rearrangements is now within reach, which impacts on all main applications of IG/TR immunogenetic analysis. To bridge the generation gap from low- to high-throughput analysis, the EuroClonality-NGS Consortium has been formed, with the main objectives to develop, standardize, and validate the entire workflow of IG/TR NGS assays for 1) clonality assessment, 2) minimal residual disease detection, and 3) repertoire analysis. This concerns the preanalytical (sample preparation, target choice), analytical (amplification, NGS), and postanalytical (immunoinformatics) phases. Here we critically discuss pitfalls and challenges of IG/TR NGS methodology and its applications in hemato-oncology and immunology., (Copyright © 2017 by The American Association of Immunologists, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
33. Challenging perspectives on the cellular origins of lymphoma.
- Author
-
Malcolm TI, Hodson DJ, Macintyre EA, and Turner SD
- Abstract
Both B and T lymphocytes have signature traits that set them apart from other cell types. They actively and repeatedly rearrange their DNA in order to produce a unique and functional antigen receptor, they have potential for massive clonal expansion upon encountering antigen via this receptor or its precursor, and they have the capacity to be extremely long lived as 'memory' cells. All three of these traits are fundamental to their ability to function as the adaptive immune response to infectious agents, but concurrently render these cells vulnerable to transformation. Thus, it is classically considered that lymphomas arise at a relatively late stage in a lymphocyte's development during the process of modifying diversity within antigen receptors, and when the cell is capable of responding to stimulus via its receptor. Attempts to understand the aetiology of lymphoma have reinforced this notion, as the most notable advances to date have shown chronic stimulation of the antigen receptor by infectious agents or self-antigens to be key drivers of these diseases. Despite this, there is still uncertainty about the cell of origin in some lymphomas, and increasing evidence that a subset arises in a more immature cell. Specifically, a recent study indicates that T-cell lymphoma, in particular nucleophosmin-anaplastic lymphoma kinase-driven anaplastic large cell lymphoma, may originate in T-cell progenitors in the thymus., (© 2016 The Authors.)
- Published
- 2016
- Full Text
- View/download PDF
34. Site- and allele-specific polycomb dysregulation in T-cell leukaemia.
- Author
-
Navarro JM, Touzart A, Pradel LC, Loosveld M, Koubi M, Fenouil R, Le Noir S, Maqbool MA, Morgado E, Gregoire C, Jaeger S, Mamessier E, Pignon C, Hacein-Bey-Abina S, Malissen B, Gut M, Gut IG, Dombret H, Macintyre EA, Howe SJ, Gaspar HB, Thrasher AJ, Ifrah N, Payet-Bornet D, Duprez E, Andrau JC, Asnafi V, and Nadel B
- Subjects
- Acetylation, Adult, Base Sequence, Basic Helix-Loop-Helix Transcription Factors metabolism, Chromatin Immunoprecipitation, DNA-Binding Proteins metabolism, Epigenesis, Genetic, Genetic Loci, Histones metabolism, Homeodomain Proteins metabolism, Humans, Jurkat Cells, Methylation, Molecular Sequence Data, Mutagenesis, Insertional, Nuclear Proteins metabolism, Plasmids genetics, Polycomb-Group Proteins metabolism, Proto-Oncogene Proteins metabolism, Survival Analysis, T-Cell Acute Lymphocytic Leukemia Protein 1, Treatment Outcome, Alleles, Gene Expression Regulation, Leukemic, Polycomb-Group Proteins genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
T-cell acute lymphoblastic leukaemias (T-ALL) are aggressive malignant proliferations characterized by high relapse rates and great genetic heterogeneity. TAL1 is amongst the most frequently deregulated oncogenes. Yet, over half of the TAL1(+) cases lack TAL1 lesions, suggesting unrecognized (epi)genetic deregulation mechanisms. Here we show that TAL1 is normally silenced in the T-cell lineage, and that the polycomb H3K27me3-repressive mark is focally diminished in TAL1(+) T-ALLs. Sequencing reveals that >20% of monoallelic TAL1(+) patients without previously known alterations display microinsertions or RAG1/2-mediated episomal reintegration in a single site 5' to TAL1. Using 'allelic-ChIP' and CrispR assays, we demonstrate that such insertions induce a selective switch from H3K27me3 to H3K27ac at the inserted but not the germline allele. We also show that, despite a considerable mechanistic diversity, the mode of oncogenic TAL1 activation, rather than expression levels, impact on clinical outcome. Altogether, these studies establish site-specific epigenetic desilencing as a mechanism of oncogenic activation.
- Published
- 2015
- Full Text
- View/download PDF
35. GSTP1 and TNF Gene variants and associations between air pollution and incident childhood asthma: the traffic, asthma and genetics (TAG) study.
- Author
-
MacIntyre EA, Brauer M, Melén E, Bauer CP, Bauer M, Berdel D, Bergström A, Brunekreef B, Chan-Yeung M, Klümper C, Fuertes E, Gehring U, Gref A, Heinrich J, Herbarth O, Kerkhof M, Koppelman GH, Kozyrskyj AL, Pershagen G, Postma DS, Thiering E, Tiesler CM, and Carlsten C
- Subjects
- Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Particulate Matter toxicity, Vehicle Emissions toxicity, Air Pollutants toxicity, Air Pollution adverse effects, Asthma chemically induced, Asthma genetics, Glutathione S-Transferase pi genetics, Tumor Necrosis Factor-alpha genetics
- Abstract
Background: Genetics may partially explain observed heterogeneity in associations between traffic-related air pollution and incident asthma., Objective: Our aim was to investigate the impact of gene variants associated with oxidative stress and inflammation on associations between air pollution and incident childhood asthma., Methods: Traffic-related air pollution, asthma, wheeze, gene variant, and potential confounder data were pooled across six birth cohorts. Parents reported physician-diagnosed asthma and wheeze from birth to 7-8 years of age (confirmed by pediatric allergist in two cohorts). Individual estimates of annual average air pollution [nitrogen dioxide (NO2), particulate matter ≤ 2.5 μm (PM2.5), PM2.5 absorbance, ozone] were assigned to each child's birth address using land use regression, atmospheric modeling, and ambient monitoring data. Effect modification by variants in GSTP1 (rs1138272/Ala114Val and rs1695/IIe105Val) and TNF (rs1800629/G-308A) was investigated., Results: Data on asthma, wheeze, potential confounders, at least one SNP of interest, and NO2 were available for 5,115 children. GSTP1 rs1138272 and TNF rs1800629 SNPs were associated with asthma and wheeze, respectively. In relation to air pollution exposure, children with one or more GSTP1 rs1138272 minor allele were at increased risk of current asthma [odds ratio (OR) = 2.59; 95% CI: 1.43, 4.68 per 10 μg/m3 NO2] and ever asthma (OR = 1.64; 95% CI: 1.06, 2.53) compared with homozygous major allele carriers (OR = 0.95; 95% CI: 0.68, 1.32 for current and OR = 1.20; 95% CI: 0.98, 1.48 for ever asthma; Bonferroni-corrected interaction p = 0.04 and 0.01, respectively). Similarly, for GSTP1 rs1695, associations between NO2 and current and ever asthma had ORs of 1.43 (95% CI: 1.03, 1.98) and 1.36 (95% CI: 1.08, 1.70), respectively, for minor allele carriers compared with ORs of 0.82 (95% CI: 0.52, 1.32) and 1.12 (95% CI: 0.84, 1.49) for homozygous major allele carriers (Bonferroni-corrected interaction p-values 0.48 and 0.09). There were no clear differences by TNF genotype., Conclusions: Children carrying GSTP1 rs1138272 or rs1695 minor alleles may constitute a susceptible population at increased risk of asthma associated with air pollution.
- Published
- 2014
- Full Text
- View/download PDF
36. Air pollution and respiratory infections during early childhood: an analysis of 10 European birth cohorts within the ESCAPE Project.
- Author
-
MacIntyre EA, Gehring U, Mölter A, Fuertes E, Klümper C, Krämer U, Quass U, Hoffmann B, Gascon M, Brunekreef B, Koppelman GH, Beelen R, Hoek G, Birk M, de Jongste JC, Smit HA, Cyrys J, Gruzieva O, Korek M, Bergström A, Agius RM, de Vocht F, Simpson A, Porta D, Forastiere F, Badaloni C, Cesaroni G, Esplugues A, Fernández-Somoano A, Lerxundi A, Sunyer J, Cirach M, Nieuwenhuijsen MJ, Pershagen G, and Heinrich J
- Subjects
- Air Pollutants toxicity, Environmental Exposure adverse effects, Female, Humans, Male, Models, Theoretical, Otitis Media chemically induced, Otitis Media epidemiology, Particulate Matter toxicity, Pneumonia chemically induced, Pneumonia epidemiology, Air Pollution adverse effects, Respiratory Tract Infections chemically induced, Respiratory Tract Infections epidemiology
- Abstract
Background: Few studies have investigated traffic-related air pollution as a risk factor for respiratory infections during early childhood., Objectives: We aimed to investigate the association between air pollution and pneumonia, croup, and otitis media in 10 European birth cohorts--BAMSE (Sweden), GASPII (Italy), GINIplus and LISAplus (Germany), MAAS (United Kingdom), PIAMA (the Netherlands), and four INMA cohorts (Spain)--and to derive combined effect estimates using meta-analysis., Methods: Parent report of physician-diagnosed pneumonia, otitis media, and croup during early childhood were assessed in relation to annual average pollutant levels [nitrogen dioxide (NO2), nitrogen oxide (NOx), particulate matter≤2.5 μm (PM2.5), PM2.5 absorbance, PM10, PM2.5-10 (coarse PM)], which were estimated using land use regression models and assigned to children based on their residential address at birth. Identical protocols were used to develop regression models for each study area as part of the ESCAPE project. Logistic regression was used to calculate adjusted effect estimates for each study, and random-effects meta-analysis was used to calculate combined estimates., Results: For pneumonia, combined adjusted odds ratios (ORs) were elevated and statistically significant for all pollutants except PM2.5 (e.g., OR=1.30; 95% CI: 1.02, 1.65 per 10-μg/m3 increase in NO2 and OR=1.76; 95% CI: 1.00, 3.09 per 10-μg/m3 PM10). For otitis media and croup, results were generally null across all analyses except for NO2 and otitis media (OR=1.09; 95% CI: 1.02, 1.16 per 10-μg/m3)., Conclusion: Our meta-analysis of 10 European birth cohorts within the ESCAPE project found consistent evidence for an association between air pollution and pneumonia in early childhood, and some evidence for an association with otitis media.
- Published
- 2014
- Full Text
- View/download PDF
37. Traffic, asthma and genetics: combining international birth cohort data to examine genetics as a mediator of traffic-related air pollution's impact on childhood asthma.
- Author
-
MacIntyre EA, Carlsten C, MacNutt M, Fuertes E, Melén E, Tiesler CM, Gehring U, Krämer U, Klümper C, Kerkhof M, Chan-Yeung M, Kozyrskyj AL, Berdel D, Bauer CP, Herbarth O, Bauer M, Schaaf B, Koletzko S, Pershagen G, Brunekreef B, Heinrich J, and Brauer M
- Subjects
- Air Pollution analysis, Asthma epidemiology, Child, Eczema epidemiology, Eczema genetics, Environmental Exposure, Female, Genotype, Glutathione S-Transferase pi genetics, Humans, Incidence, Inflammation genetics, Male, Nitrogen Dioxide adverse effects, Oxidative Stress genetics, Polymorphism, Single Nucleotide, Rhinitis epidemiology, Rhinitis genetics, Tumor Necrosis Factor-alpha genetics, Air Pollution adverse effects, Asthma genetics, Gene-Environment Interaction, Vehicle Emissions toxicity
- Abstract
Associations between traffic-related air pollution and incident childhood asthma can be strengthened by analysis of gene-environment interactions, but studies have typically been limited by lack of study power. We combined data from six birth cohorts on: asthma, eczema and allergic rhinitis to 7/8 years, and candidate genes. Individual-level assessment of traffic-related air pollution exposure was estimated using land use regression or dispersion modeling. A total of 11,760 children were included in the Traffic, Asthma and Genetics (TAG) Study; 6.3 % reported physician-diagnosed asthma at school-age, 16.0 % had asthma at anytime during childhood, 14.1 % had allergic rhinitis at school-age, 10.0 % had eczema at school-age and 33.1 % were sensitized to any allergen. For GSTP1 rs1138272, the prevalence of heterozygosity was 16 % (range amongst individual cohorts, 11-17 %) and homozygosity for the minor allele was 1 % (0-2 %). For GSTP1 rs1695, the prevalence of heterozygosity was 45 % (40-48 %) and homozygosity for the minor allele, 12 % (10-12 %). For TNF rs1800629, the prevalence of heterozygosity was 29 % (25-32 %) and homozygosity for the minor allele, 3 % (1-3 %). TAG comprises a rich database, the largest of its kind, for investigating the effect of genotype on the association between air pollution and childhood allergic disease.
- Published
- 2013
- Full Text
- View/download PDF
38. Otitis media in infancy and the development of asthma and atopic disease.
- Author
-
MacIntyre EA and Heinrich J
- Subjects
- Age Distribution, Age of Onset, Child, Child, Preschool, Cohort Studies, Comorbidity, Eczema epidemiology, Humans, Incidence, Infant, Rhinitis, Allergic, Seasonal epidemiology, Risk Factors, Asthma epidemiology, Hypersensitivity, Immediate epidemiology, Otitis Media epidemiology, Respiratory Tract Infections epidemiology
- Abstract
Otitis media is a frequent respiratory infection of early childhood and it is important to fully understand the long-term complications and sequelae. Literature examining otitis media in early childhood and subsequent development of atopic disease is sparse despite there being vast literature on the association between respiratory infections and atopic disease. Current data support the hypothesis that otitis media infections in early life, especially frequent or severe infections, influence the developing immune system, resulting in increased risk for asthma. Recent findings have also reported an association between otitis media and eczema. Atopic children and those with a family history of atopy appear to be at greater risk. Future work should investigate the specific mechanisms involved. It is possible that vaccines and preventive strategies aimed at reducing the burden of otitis media could also reduce the burden of childhood asthma and atopic disease.
- Published
- 2012
- Full Text
- View/download PDF
39. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations.
- Author
-
Langerak AW, Groenen PJ, Brüggemann M, Beldjord K, Bellan C, Bonello L, Boone E, Carter GI, Catherwood M, Davi F, Delfau-Larue MH, Diss T, Evans PA, Gameiro P, Garcia Sanz R, Gonzalez D, Grand D, Håkansson A, Hummel M, Liu H, Lombardia L, Macintyre EA, Milner BJ, Montes-Moreno S, Schuuring E, Spaargaren M, Hodges E, and van Dongen JJ
- Subjects
- DNA analysis, Gene Rearrangement, Guidelines as Topic, Humans, Lymphoproliferative Disorders genetics, Multiplex Polymerase Chain Reaction, Immunoglobulins genetics, Lymphoproliferative Disorders diagnosis, Receptors, Antigen, T-Cell genetics
- Abstract
PCR-based immunoglobulin (Ig)/T-cell receptor (TCR) clonality testing in suspected lymphoproliferations has largely been standardized and has consequently become technically feasible in a routine diagnostic setting. Standardization of the pre-analytical and post-analytical phases is now essential to prevent misinterpretation and incorrect conclusions derived from clonality data. As clonality testing is not a quantitative assay, but rather concerns recognition of molecular patterns, guidelines for reliable interpretation and reporting are mandatory. Here, the EuroClonality (BIOMED-2) consortium summarizes important pre- and post-analytical aspects of clonality testing, provides guidelines for interpretation of clonality testing results, and presents a uniform way to report the results of the Ig/TCR assays. Starting from an immunobiological concept, two levels to report Ig/TCR profiles are discerned: the technical description of individual (multiplex) PCR reactions and the overall molecular conclusion for B and T cells. Collectively, the EuroClonality (BIOMED-2) guidelines and consensus reporting system should help to improve the general performance level of clonality assessment and interpretation, which will directly impact on routine clinical management (standardized best-practice) in patients with suspected lymphoproliferations.
- Published
- 2012
- Full Text
- View/download PDF
40. Dynamics of human prothymocytes and xenogeneic thymopoiesis in hematopoietic stem cell-engrafted nonobese diabetic-SCID/IL-2rγnull mice.
- Author
-
Parietti V, Nelson E, Telliam G, Le Noir S, Pla M, Delord M, Vanneaux V, Mohtashami M, Macintyre EA, Gluckman JC, Asnafi V, Zúñiga-Pflücker JC, Larghero J, and Canque B
- Subjects
- Animals, Bone Marrow Cells cytology, Cell Lineage immunology, Hematopoietic Stem Cell Transplantation, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Oligonucleotide Array Sequence Analysis, Reverse Transcriptase Polymerase Chain Reaction, Transplantation, Heterologous, Cell Differentiation immunology, Lymphoid Progenitor Cells cytology, Lymphopoiesis physiology, T-Lymphocytes cytology, Thymus Gland cytology
- Abstract
To model the developmental pattern of human prothymocytes and thymopoiesis, we used NOD-scid/γc(-/-) mice grafted with human umbilical cord blood CD34(+) hematopoietic progenitor cells (HPCs). Human prothymocytes developed in the murine bone marrow (BM) from multipotent CD34(++)CD38(lo)lineage(-) HPCs to CD34(++)CD7(+)CD2(-) pro-T1 cells that progressed in a Notch-dependent manner to CD34(+)CD7(++)CD2(+) pro-T2 cells, which migrated to the thymus. BM prothymocyte numbers peaked 1 mo after graft, dropped at mo 2, and persisted at low levels thereafter, with only a few CD34(+)CD7(lo) prothymocytes with limited T potential being detected by mo 5. As a consequence, thymopoiesis in this xenogeneic setting began by weeks 4-6, peaked at mo 3, and decreased thenceforth. Analyzing mice grafted at 2, 4 or 8, mo of age showed that in an "older" BM, prothymocyte differentiation was perturbed and resulted in CD34(+)CD7(lo) prothymocytes with limited T potential. Whereas the early drop in BM thymopoietic activity was related to a Notch-independent loss of T potential by CD34(++)CD38(lo)lineage(-) HPCs, the later age-dependent production decline of prothymocytes was linked to a more complex mix of cell-intrinsic and microenvironmental defects. Accordingly, and contrasting with what was observed with umbilical cord blood HPCs, CD34(+) HPCs from human adult BM displayed only marginal thymopoietic activity when grafted into young 2-mo-old NOD-scid/γc(-/-) mice. These data demonstrate that the developmental pattern of BM prothymocytes during human late fetal and early postnatal life can be reproduced in humanized mice, and they suggest that onset of human thymus involution relates to decreased colonization by prothymocytes.
- Published
- 2012
- Full Text
- View/download PDF
41. TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRα gene expression.
- Author
-
Dadi S, Le Noir S, Payet-Bornet D, Lhermitte L, Zacarias-Cabeza J, Bergeron J, Villarèse P, Vachez E, Dik WA, Millien C, Radford I, Verhoeyen E, Cosset FL, Petit A, Ifrah N, Dombret H, Hermine O, Spicuglia S, Langerak AW, Macintyre EA, Nadel B, Ferrier P, and Asnafi V
- Subjects
- Apoptosis, Binding Sites, Gene Rearrangement, HeLa Cells, Homeodomain Proteins genetics, Homeodomain Proteins metabolism, Humans, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma pathology, Protein Structure, Tertiary, Proto-Oncogene Protein c-ets-1 physiology, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, Gene Expression Regulation, Neoplastic, Genes, T-Cell Receptor alpha, Homeodomain Proteins physiology, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma genetics, Proto-Oncogene Protein c-ets-1 metabolism, Proto-Oncogene Proteins physiology
- Abstract
Acute lymphoblastic leukemias (ALLs) are characterized by multistep oncogenic processes leading to cell-differentiation arrest and proliferation. Specific abrogation of maturation blockage constitutes a promising therapeutic option in cancer, which requires precise understanding of the underlying molecular mechanisms. We show that the cortical thymic maturation arrest in T-lineage ALLs that overexpress TLX1 or TLX3 is due to binding of TLX1/TLX3 to ETS1, leading to repression of T cell receptor (TCR) α enhanceosome activity and blocked TCR-Jα rearrangement. TLX1/TLX3 abrogation or enforced TCRαβ expression leads to TCRα rearrangement and apoptosis. Importantly, the autoextinction of clones carrying TCRα-driven TLX1 expression supports TLX "addiction" in TLX-positive leukemias and provides further rationale for targeted therapy based on disruption of TLX1/TLX3., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
42. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia.
- Author
-
Bonnet M, Loosveld M, Montpellier B, Navarro JM, Quilichini B, Picard C, Di Cristofaro J, Bagnis C, Fossat C, Hernandez L, Mamessier E, Roulland S, Morgado E, Formisano-Tréziny C, Dik WA, Langerak AW, Prebet T, Vey N, Michel G, Gabert J, Soulier J, Macintyre EA, Asnafi V, Payet-Bornet D, and Nadel B
- Subjects
- Adult, Cells, Cultured, Child, Gene Expression Regulation, Leukemic, Humans, Jurkat Cells, PTEN Phosphohydrolase genetics, PTEN Phosphohydrolase metabolism, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma pathology, RNA Processing, Post-Transcriptional genetics, RNA Processing, Post-Transcriptional physiology, Signal Transduction genetics, Transcriptional Activation genetics, Transfection, Genes, myc, PTEN Phosphohydrolase physiology, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
Cumulative evidence indicates that MYC, one of the major downstream effectors of NOTCH1, is a critical component of T-cell acute lymphoblastic leukemia (T-ALL) oncogenesis and a potential candidate for targeted therapy. However, MYC is a complex oncogene, involving both fine protein dosage and cell-context dependency, and detailed understanding of MYC-mediated oncogenesis in T-ALL is still lacking. To better understand how MYC is interspersed in the complex T-ALL oncogenic networks, we performed a thorough molecular and biochemical analysis of MYC activation in a comprehensive collection of primary adult and pediatric patient samples. We find that MYC expression is highly variable, and that high MYC expression levels can be generated in a large number of cases in absence of NOTCH1/FBXW7 mutations, suggesting the occurrence of multiple activation pathways in addition to NOTCH1. Furthermore, we show that posttranscriptional deregulation of MYC constitutes a major alternative pathway of MYC activation in T-ALL, operating partly via the PI3K/AKT axis through down-regulation of PTEN, and that NOTCH1(m) might play a dual transcriptional and posttranscriptional role in this process. Altogether, our data lend further support to the significance of therapeutic targeting of MYC and/or the PTEN/AKT pathways, both in GSI-resistant and identified NOTCH1-independent/MYC-mediated T-ALL patients.
- Published
- 2011
- Full Text
- View/download PDF
43. Residential air pollution and otitis media during the first two years of life.
- Author
-
MacIntyre EA, Karr CJ, Koehoorn M, Demers PA, Tamburic L, Lencar C, and Brauer M
- Subjects
- Adolescent, Adult, Ambulatory Care Facilities statistics & numerical data, British Columbia, Child, Preschool, Cohort Studies, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk, Young Adult, Air Pollutants adverse effects, Otitis Media epidemiology
- Abstract
Background: : Otitis media is the leading reason young children receive antibiotics or visit a physician. We evaluated the impact of ambient air pollution on outpatient physician visits for otitis media in a population-based birth cohort., Methods: : All children born in southwestern British Columbia during 1999-2000 were followed until the age of 2 years. Residential air pollution exposures were estimated for the first 24 months of life by inverse-distance weighting of monitor data (CO, NO, NO2, O3, PM2.5, PM10, SO2), temporally adjusted land-use regression models (NO, NO2, PM2.5, black carbon, woodsmoke), and proximity to roads and point sources. We used generalized estimating equations to longitudinally assess the relationship between physician visits for otitis media (ICD-9) and average pollutant exposure in the 2 months prior to the visit, after adjustment for covariates., Results: : Complete exposure and risk-factor data were available for 45,513 children (76% of all births). A total of 42% of subjects had 1 or more physician visits for otitis media during follow-up. Adjusted estimates for NO, PM2.5, and woodsmoke were consistently elevated (eg, relative risk of 1.10 [95% confidence interval = 1.07-1.12] per interquartile range [IQR] increase in NO; 1.32 [1.27-1.36] per IQR increase in days of woodsmoke exposure). No increased risks were observed for the remaining pollutants (eg, 1.00 [0.98-1.03] per IQR increase in PM10; 0.99 [0.97-1.01] per IQR increase in black carbon)., Conclusions: : Modest but consistent associations were found between some measures of air pollution and otitis media in a large birth cohort exposed to relatively low levels of ambient air pollution.
- Published
- 2011
- Full Text
- View/download PDF
44. Early-life otitis media and incident atopic disease at school age in a birth cohort.
- Author
-
MacIntyre EA, Chen CM, Herbarth O, Borte M, Schaaf B, Krämer U, von Berg A, Wichmann HE, and Heinrich J
- Subjects
- Child, Child, Preschool, Cohort Studies, Female, Germany, Humans, Infant, Infant, Newborn, Male, Parents, Surveys and Questionnaires, Hypersensitivity, Immediate epidemiology, Otitis Media epidemiology
- Abstract
Background: Otitis media is a common and costly disease that peaks in early childhood. Recent reviews concluded that the relationship between otitis media and atopy is not well understood, and that further research is warranted., Methods: Logistic regression was used to analyze data from a German Birth Cohort (n = 1690; born 1997–1999). Parental questionnaires were used to assess children for physician-diagnosed otitis media throughout the first 2 years of life and for incident atopic disease (asthma, allergic rhinitis, and eczema) during the sixth year of life. Odds ratios were adjusted for gender, older siblings, city, parental education, breast-feeding, and daycare. Parallel analyses were completed for the full birth cohort and for a population subset with atopic mothers., Results: The adjusted odds of asthma were elevated for children with early-life otitis media, but were statistically significant only for those children with at least 3 episodes (adjusted odds ratio: 4.26 [95% confidence interval: 1.34–13.6]). Associations between early-life otitis media and allergic rhinitis were largely inconsistent. There was a positive association between early-life otitis media and late-onset allergic eczema (≥2 episodes: 2.68 [1.35–5.33], ≥3 episodes: 3.84 [1.80–8.18]). Similar results were found for the maternal atopy subgroup but with greater effect estimates., Conclusions: Children diagnosed with otitis media during infancy were at greater risk for developing late-onset allergic eczema and asthma during school age, and associations were stronger for frequent otitis. These results indicate that frequent otitis media during infancy may predispose children to atopic disease in later life.
- Published
- 2010
- Full Text
- View/download PDF
45. Otitis media incidence and risk factors in a population-based birth cohort.
- Author
-
Macintyre EA, Karr CJ, Koehoorn M, Demers P, Tamburic L, Lencar C, and Brauer M
- Abstract
Background: Otitis media is the main reason young children receive antibiotics and is the leading reason for physician visits., Objective: To characterize the incidence, recurrence and risk factors for otitis media in a population-based birth cohort., Methods: All children born in southwestern British Columbia during 1999 to 2000 were followed until the age of three years. Otitis media was defined using The International Classification of Diseases, Ninth Revision coding of physician visits, and linked with antibiotic prescription data. Information on sex, birth weight, gestational age, Aboriginal status, maternal age, older siblings, maternal smoking during pregnancy, breastfeeding initiation, neighbourhood income, female education and rural residence were obtained from vital statistics, birth hospitalizations, perinatal registry and census data., Results: Complete risk factor information was available for 50,474 children (86% of all births). Nearly one-half of the children (48.6%) had one or more physician visits for otitis media during follow-up, and 3952 children (7.8%) met the definition for recurrent otitis media. Of the children with at least three visits during follow-up (n=7571), 73% had their initial visit during the first year of life. Aboriginal status, maternal age younger than 20 years, male sex and older siblings were the strongest risk factors identified in the adjusted conditional logistic regression models., Discussion: The present study established a population-based birth cohort by linking multiple administrative databases to characterize the incidence of and risk factors for otitis media. Although the incidence of otitis media is generally low in southwestern British Columbia, important risk factors continue to be young maternal age, mothers who smoke during pregnancy and children with Aboriginal ancestry.
- Published
- 2010
- Full Text
- View/download PDF
46. Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience.
- Author
-
Guièze R, Renneville A, Cayuela JM, Abdelali RB, Boissel N, de Botton S, Rubio MT, Mazingue F, Macintyre EA, Cheok M, Sigaux F, Fenaux P, Dombret H, and Preudhomme C
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Child, Preschool, Chromosomes, Human, Pair 16 genetics, Female, France, Gene Rearrangement, Humans, Leukemia, Myeloid, Acute drug therapy, Male, Middle Aged, Neoplasm, Residual drug therapy, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, Neoplasm, Residual diagnosis, Neoplasm, Residual genetics, Oncogene Proteins, Fusion genetics
- Published
- 2010
- Full Text
- View/download PDF
47. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia.
- Author
-
Chapiro E, Russell L, Lainey E, Kaltenbach S, Ragu C, Della-Valle V, Hanssens K, Macintyre EA, Radford-Weiss I, Delabesse E, Cavé H, Mercher T, Harrison CJ, Nguyen-Khac F, Dubreuil P, and Bernard OA
- Subjects
- Humans, Janus Kinase 2 genetics, Mutation, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Receptors, Cytokine genetics
- Published
- 2010
- Full Text
- View/download PDF
48. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
- Author
-
Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, and van Dongen JJ
- Subjects
- Flow Cytometry, Fusion Proteins, bcr-abl genetics, Gene Rearrangement, Genes, Immunoglobulin, Humans, Neoplasm, Residual diagnosis, Polymerase Chain Reaction, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis
- Abstract
Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR- and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.
- Published
- 2010
- Full Text
- View/download PDF
49. Cyclin D3 deregulation by juxtaposition with IGH locus in a t(6;14)(p21;q32)-positive T-cell acute lymphoblastic leukemia.
- Author
-
Nguyen-Khac F, Barin C, Chapiro E, Macintyre EA, Romana S, and Bernard OA
- Subjects
- Child, Flow Cytometry, Humans, In Situ Hybridization, Fluorescence, Male, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 6, Cyclin D3 metabolism, Immunoglobulin Heavy Chains genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma genetics, Translocation, Genetic
- Published
- 2010
- Full Text
- View/download PDF
50. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.
- Author
-
Familiades J, Bousquet M, Lafage-Pochitaloff M, Béné MC, Beldjord K, De Vos J, Dastugue N, Coyaud E, Struski S, Quelen C, Prade-Houdellier N, Dobbelstein S, Cayuela JM, Soulier J, Grardel N, Preudhomme C, Cavé H, Blanchet O, Lhéritier V, Delannoy A, Chalandon Y, Ifrah N, Pigneux A, Brousset P, Macintyre EA, Huguet F, Dombret H, Broccardo C, and Delabesse E
- Subjects
- Adolescent, Adult, Antineoplastic Agents therapeutic use, Benzamides, Clinical Trials, Phase II as Topic, Gene Dosage, Gene Rearrangement, T-Lymphocyte genetics, Genomics, Haplotypes, Humans, Imatinib Mesylate, Immunoglobulin Heavy Chains genetics, Immunophenotyping, Middle Aged, Multicenter Studies as Topic, Piperazines therapeutic use, Point Mutation, Pre-B-Cell Leukemia Transcription Factor 1, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Prognosis, Prospective Studies, Pyrimidines therapeutic use, Young Adult, Basic Helix-Loop-Helix Transcription Factors genetics, DNA-Binding Proteins genetics, Fusion Proteins, bcr-abl genetics, PAX5 Transcription Factor genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Proto-Oncogene Proteins genetics
- Abstract
Adult and child B-cell progenitor acute lymphoblastic leukemia (BCP-ALL) differ in terms of incidence and prognosis. These disparities are mainly due to the molecular abnormalities associated with these two clinical entities. A genome-wide analysis using oligo SNP arrays recently demonstrated that PAX5 (paired-box domain 5) is the main target of somatic mutations in childhood BCP-ALL being altered in 38.9% of the cases. We report here the most extensive analysis of alterations of PAX5 coding sequence in 117 adult BCP-ALL patients in the unique clinical protocol GRAALL-2003/GRAAPH-2003. Our study demonstrates that PAX5 is mutated in 34% of adult BCP-ALL, mutations being partial or complete deletion, partial or complete amplification, point mutation or fusion gene. PAX5 alterations are heterogeneous consisting in complete loss in 17%, focal deletions in 10%, point mutations in 7% and translocations in 1% of the cases. PAX5 complete loss and PAX5 point mutations differ. PAX5 complete loss seems to be a secondary event and is significantly associated with BCR-ABL1 or TCF3-PBX1 fusion genes and a lower white blood cell count.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.